

Regno Unito-Bristol: Servizi di patologia

OJ S 21/2020 30/01/2020

Avviso volontario per la trasparenza ex ante

Servizi

**Base giuridica:**

Direttiva 2014/24/UE

## Sezione I: Amministrazione aggiudicatrice/ente aggiudicatore

---

### I.1. Denominazione e indirizzi

Denominazione ufficiale: North Bristol NHS Trust

Indirizzo postale: Southmead Road, Bristol

Città: Bristol

Codice NUTS: UKK11 Bristol, City of

Codice postale: BS10 5NB

Paese: Regno Unito

Persona di contatto: Martin Strawson

E-mail: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)

Tel.: +44 1173420815

**Indirizzi Internet:**

Indirizzo principale: <https://www.nbt.nhs.uk/>

### I.4. Tipo di amministrazione aggiudicatrice

Altro tipo: NHS trust

### I.5. Principali settori di attività

Salute

## Sezione II: Oggetto

---

### II.1. Entità dell'appalto

#### II.1.1. Denominazione

Procurement of a Large Throughput DNA Sequencer

Numero di riferimento: BWPCCL001501

#### II.1.2. Codice CPV principale

85111800 Servizi di patologia

#### II.1.3. Tipo di appalto

Servizi

#### II.1.4. Breve descrizione

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

#### **II.1.6. Informazioni relative ai lotti**

Questo appalto è suddiviso in lotti: no

#### **II.1.7. Valore totale dell'appalto**

Valore, IVA esclusa: 779 625,00 GBP

### **II.2. Descrizione**

#### **II.2.2. Codici CPV supplementari**

85111000 Servizi ospedalieri

#### **II.2.3. Luogo di esecuzione**

Codice NUTS: UKK11 Bristol, City of

#### **II.2.4. Descrizione dell'appalto**

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### **II.2.5. Criteri di aggiudicazione**

Criterio di qualità - Nome: Quality / Ponderazione: 90

Prezzo - Ponderazione: 10

#### **II.2.11.**

## Informazioni relative alle opzioni

Opzioni: no

### II.2.13. Informazioni relative ai fondi dell'Unione europea

L'appalto è connesso ad un progetto e/o programma finanziato da fondi dell'Unione europea:  
no

### II.2.14. Informazioni complementari

## Sezione IV: Procedura

---

### IV.1. Descrizione

#### IV.1.1. Tipo di procedura

Aggiudicazione di un appalto senza previa pubblicazione di un avviso di indizione di gara nella Gazzetta ufficiale dell'Unione europea nei casi elencati di seguito

- L'appalto non rientra nel campo di applicazione della direttiva

Spiegazione:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

#### IV.1.3. Informazioni relative all'accordo quadro

#### IV.1.8. Informazioni relative all'accordo sugli appalti pubblici (AAP)

L'appalto è disciplinato dall'accordo sugli appalti pubblici: no

## IV.2. Informazioni di carattere amministrativo

### Sezione V: Aggiudicazione dell'appalto/della concessione

---

**Denominazione:**

Procurement of Large High Throughput DNA Sequencer

#### V.2. Aggiudicazione dell'appalto/della concessione

##### V.2.1. Data della decisione di aggiudicazione dell'appalto

28/01/2020

##### V.2.2. Informazioni sulle offerte

L'appalto è stato aggiudicato a un raggruppamento di operatori economici: no

##### V.2.3. Denominazione e indirizzo del contraente/concessionario

Denominazione ufficiale: Illumina Cambridge Ltd

Indirizzo postale: Chesterford Research Park, Little Chesterford

Città: Saffron Walden

Codice NUTS: UKI London

Codice postale: CB10 1XL

Paese: Regno Unito

Il futuro contraente/concessionario è una PMI: sì

##### V.2.4. Informazioni relative al valore del contratto d'appalto/del lotto/della concessione

Valore totale del contratto d'appalto/del lotto/della concessione: 779 625,00 GBP

##### V.2.5. Informazioni sui subappalti

### Sezione VI: Altre informazioni

---

#### VI.3. Informazioni complementari

#### VI.4. Procedure di ricorso

##### VI.4.1. Organismo responsabile delle procedure di ricorso

Denominazione ufficiale: Bristol and Weston Purchasing Consortium

Indirizzo postale: Level 3, Whitefriars, Lewins Mead

Città: Bristol

Codice postale: BS1 2NT

Paese: Regno Unito

E-mail: [martin.strawson@UHBristol.nhs.uk](mailto:martin.strawson@UHBristol.nhs.uk)

##### VI.4.2. Organismo responsabile delle procedure di mediazione

Denominazione ufficiale: Bristol and Weston Purchasing Consortium

Indirizzo postale: Level 3, Whitefriars, Lewins Mead

Città: Bristol

Codice postale: BS1 2NT

Paese: Regno Unito

##### VI.4.4. Servizio presso il quale sono disponibili informazioni sulle procedure di ricorso

Denominazione ufficiale: Bristol and Weston Purchasing Consortium

Indirizzo postale: Level 3, Whitefriars, Lewins Mead

Città: Bristol  
Codice postale: BS1 2NT  
Paese: Regno Unito

**VI.5. Data di spedizione del presente avviso**  
28/01/2020